Etoricoxib

Synonyms: Etoricoxib, 5-chloro-6′-methyl-3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine, MK-0663, Arcoxia, Algix, Tauxib, Nucoxia

Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor developed by Merck & Co. as a follow-up to rofecoxib. It belongs to the bipyridine class and is structurally distinct from other coxibs, featuring a methylsulfonyl phenyl group attached to a chlorinated bipyridine core. Clinically, it is used for the treatment of osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and moderate to severe pain, offering comparable efficacy to traditional NSAIDs with a reduced risk of gastrointestinal ulceration.

The drug’s selectivity for COX-2 over COX-1 is a key differentiator. At therapeutic doses, etoricoxib inhibits COX-2-mediated prostaglandin production at sites of inflammation without significantly affecting COX-1-dependent thromboxane A2 production in platelets. This profile translates to effective pain relief and anti-inflammatory action with less impact on gastric mucosal integrity compared to non-selective NSAIDs.

In the pharmaceutical industry, etoricoxib is supplied as a high-purity active pharmaceutical ingredient (API) for oral tablet formulations. It is also used as a reference standard in analytical laboratories and as a research chemical for studying COX-2 biology and inflammatory pathways. The global demand for etoricoxib API remains strong, particularly in Europe, Asia, and Latin America, where it is approved for a range of musculoskeletal conditions.

Function & Mechanism

• Selective COX-2 inhibition: Blocks cyclooxygenase-2 enzyme, reducing prostaglandin synthesis at inflammatory sites.
• Anti-inflammatory activity: Decreases swelling, redness, and pain associated with arthritis and gout.
• Analgesic effect: Provides relief from acute pain, including dental and post-surgical pain.
• Antipyretic action: Reduces fever by inhibiting prostaglandin E2 production in the hypothalamus.
• Gastrointestinal safety: Spares COX-1, leading to lower incidence of gastric ulcers compared to non-selective NSAIDs.

Source et normalisation

• Source: Synthetic chemical synthesis.
• Manufacturing: Multi-step organic synthesis followed by purification and crystallization.
• Normalisation: ≥99.0% purity by HPLC, conforming to pharmacopeial monographs (e.g., Ph. Eur., USP).
• Formulaires: White to off-white crystalline powder.
• Applications: Pharmaceutical manufacturing (tablets), analytical reference standards, research studies.

Quality Specifications (QC Tests)

Bulk Supply & Documentation

• Capacité mensuelle: 500 kg
• Délai de livraison: 3 à 5 jours ouvrés (articles en stock)
• Documentation: Certificat d'analyse (COA), fiche de données de sécurité (FDS) et fiche technique (TDS) disponibles sur demande
• Emballage: 1 kg, 5 kg, 25 kg double polyethylene bags inside fiber drums

Foire aux questions

What is the minimum order quantity (MOQ) for Etoricoxib?

Our MOQ is 1 kg for standard orders. For larger quantities, we offer competitive pricing and flexible packaging options.

What is the delivery time?

We maintain stock of Etoricoxib, and orders are typically dispatched within 3-5 business days after order confirmation.

Do you provide a Certificate of Analysis (COA) and samples?

Yes, a COA is available for each batch. We can provide samples for evaluation upon request; sample dispatch is usually arranged within 1-2 days.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

send us your specification for a quotation.